SenesTech (SNES) 10-Q 8 Aug 24 2024 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Jun. 30, 2024	Aug. 06, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-37941
Entity Registrant Name	SENESTECH, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	20-2079805
Entity Address, Address Line One	23460 N 19th Ave,
Entity Address, Address Line Two	Suite 110
Entity Address, City or Town	Phoenix
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85027
City Area Code	(928)
Local Phone Number	779-4143
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	SNES
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		515,340
Entity Central Index Key	0001680378
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Amendment Flag	false

CONDENSED BALANCE SHEETS

CONDENSED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 1,952	$ 5,395
Accounts receivable, net	243	95
Prepaid expenses and other current assets	464	388
Inventory, net	899	795
Total current assets	3,558	6,673
Right to use assets, operating leases	97	210
Property and equipment, net	360	388
Other noncurrent assets	22	22
Total assets	4,037	7,293
Current liabilities:
Accounts payable	191	150
Accrued expenses	415	368
Current portion of operating lease liability	101	217
Current portion of notes payable	39	33
Deferred revenue	15	18
Total current liabilities	761	786
Notes payable, less current portion	162	156
Total liabilities	923	942
Commitments and contingencies (see notes)
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.001 par value, 100,000,000 shares authorized, 515,340 shares and 514,003 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively	1	1
Additional paid-in capital	136,442	136,263
Accumulated deficit	(133,329)	(129,913)
Total stockholders’ equity	3,114	6,351
Total liabilities and stockholders’ equity	$ 4,037	$ 7,293

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	515,340	514,003
Common stock, shares outstanding (in shares)	515,340	514,003

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Income Statement [Abstract]
Revenues, net	$ 459	$ 305	$ 874	$ 538
Cost of sales	210	163	490	304
Gross profit	249	142	384	234
Operating expenses:
Research and development	467	381	837	768
Selling, general and administrative	1,384	1,761	2,992	3,511
Total operating expenses	1,851	2,142	3,829	4,279
Loss from operations	(1,602)	(2,000)	(3,445)	(4,045)
Other income (expense):
Interest income	22	7	37	15
Interest expense	(5)	0	(9)	0
Miscellaneous income	1	0	1	0
Other income, net	18	7	29	15
Net loss	(1,584)	(1,993)	(3,416)	(4,030)
Comprehensive loss	$ (1,584)	$ (1,993)	$ (3,416)	$ (4,030)
Weighted average shares outstanding - basic (in shares)	514,463	23,841	514,458	20,492
Weighted average shares outstanding - diluted (in shares)	514,463	23,841	514,458	20,492
Net loss per share - basic (in dollars per share)	$ (3.08)	$ (83.58)	$ (6.64)	$ (196.66)
Net loss per share - diluted (in dollars per share)	$ (3.08)	$ (83.58)	$ (6.64)	$ (196.66)

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net loss	$ (3,416)	$ (4,030)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	73	69
Stock-based compensation	173	336
Bad debt expense	2	(2)
Changes in operating assets and liabilities:
Accounts receivable	(150)	71
Prepaid expenses and other current assets	(76)	92
Inventory	(104)	88
Other assets	(3)	(2)
Accounts payable	41	(420)
Accrued expenses	47	61
Deferred revenue	(3)	(20)
Net cash used in operating activities	(3,416)	(3,757)
Cash flows from investing activities:
Purchase of property and equipment	(41)	(21)
Net cash used in investing activities	(41)	(21)
Cash flows from financing activities:
Proceeds from issuances of common stock, net	0	1,210
Proceeds from issuance of notes payable	25	0
Repayments of notes payable	(17)	0
Proceeds from the exercise of warrants	6	0
Payment of employee withholding taxes related to share based awards	0	(11)
Net cash provided by financing activities	14	1,199
Decrease in cash and cash equivalents	(3,443)	(2,579)
Cash and cash equivalents, beginning of period	5,395	4,775
Cash and cash equivalents, end of period	1,952	2,196
Supplemental cash flow information is as follows:
Interest paid	9	0
Income taxes paid	0	0
Non-cash investing and financing activities:
Note payable incurred for the purchase of certain equipment	$ 4	$ 0

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Nature of Business SenesTech, Inc. (subsequently referred to in this report as “we,” “us,” “our,” or “our company”) was incorporated in the state of Nevada in July 2004. On November 12, 2015, we subsequently reincorporated in the state of Delaware. Our corporate headquarters and manufacturing site are in Phoenix, Arizona. We have developed and are commercializing a global, proprietary technology for managing animal pest populations, initially rat populations, through fertility control. Our current products are known as ContraPest ® and Evolve TM . Our initial product was ContraPest, which is a liquid bait containing the active ingredients 4-vinylcyclohexene diepoxide and triptolide. ContraPest limits reproduction of male and female rats beginning with the first breeding cycle following consumption. ContraPest is being marketed for use in controlling Norway and roof rat populations. In addition to the U.S. Environmental Protection Agency (“EPA”) registration of ContraPest, we must obtain registration from the various state regulatory agencies prior to selling in each state. To date, we have received registration for ContraPest in all 50 states and the District of Columbia, 49 of which have approved the removal of the Restricted Use designation, as well as the District of Columbia and five major U.S. territories. In January 2024, we launched Evolve, which is a soft bait containing the active ingredient cottonseed oil. Evolve limits reproduction of male and female rats beginning with the first breeding cycle following consumption. Evolve is considered a minimum risk pesticide under the EPA Federal Insecticide, Fungicide, and Rodenticide Act, Section 25(b) (“Section 25(b)”). We must obtain registration from the various state regulatory agencies that do not accept the federal exemption. To date, we are authorized to sell Evolve in 43 states. In May 2024, we launched our latest product Evolve Mouse, a modified version of our soft bait technology containing the active ingredient cottonseed oil. Evolve Mouse limits reproduction of male and female mice after one to two breeding cycles following consumption. Evolve Mouse is also considered a minimum risk pesticide under Section 25(b). We must obtain registration from the various state regulatory agencies that do not accept the federal exemption. To date, we are authorized to sell Evolve Mouse in 32 states. Going Concern Our condensed financial statements as of June 30, 2024 were prepared under the assumption that we would continue as a going concern. The reports of our independent registered public accounting firm that accompanies our financial statements for each of the years ended December 31, 2023 and December 31, 2022 contain a going concern qualification in which such firm expressed substantial doubt about our ability to continue as a going concern, based on the financial statements at that time. Specifically, we have incurred operating losses since our inception, and we expect to continue to incur significant expenses and operating losses for the foreseeable future. These prior losses and expected future losses have had, and will continue to have, an adverse effect on our financial condition. If we encounter continued issues or delays in the commercialization of fertility control products, our expected future losses could have an adverse effect on our financial condition and negatively impact our ability to fund continued operations, obtain additional financing in the future and continue as a going concern. There are no assurances that such financing, if necessary, will be available to us at all or will be available in sufficient amounts or on reasonable terms. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty. If we are unable to generate additional funds in the future through additional financings, sales of our products, licensing fees, royalty payments or from other sources or transactions, we will exhaust our resources and will be unable to continue operations. Liquidity and Capital Resources Since our inception, we have sustained significant operating losses in the course of our research and development and commercialization activities and expect such losses to continue for the near future. We have generated limited revenue to date from product sales, research grants and licensing fees received under a former license agreement. We have primarily funded our operations to date through the sale of equity securities, including convertible preferred stock, common stock and warrants to purchase common stock. We have also raised capital through debt financing, consisting primarily of convertible notes and government loan programs, and, to a lesser extent, payments received in connection with product sales, research grants and licensing fees. As of June 30, 2024, we had an accumulated deficit of $133.3 million and cash and cash equivalents of $2.0 million. Our ultimate success depends upon the outcome of a combination of factors, including the following: (i) successful commercialization of fertility control products and maintaining and obtaining regulatory approval of our products and product candidates; (ii) market acceptance, commercial viability and profitability of fertility control products and other products; (iii) the ability to market our products and establish an effective sales force and marketing infrastructure to generate significant revenue; (iv) the success of our research and development; (v) the ability to retain and attract key personnel to develop, operate and grow our business; and (vi) our ability to meet our working capital needs. Based upon our current operating plan, we expect that cash and cash equivalents at June 30, 2024, in combination with anticipated revenue and any additional sales of our equity securities, will be sufficient to fund our current operations for at least the next three months. While we have evaluated and continue to evaluate our operating expenses and concentrate our resources toward the successful commercialization of fertility control products in the United States, additional financing will be needed before achieving anticipated revenue targets and margin targets. If we are unable to raise necessary capital through the sale of our securities, we may be required to take other measures that could impair our ability to be successful and operate as a going concern. In any event, additional capital is needed in order to fund our operating losses and research and development activities before we become profitable. We may never achieve profitability or generate positive cash flows, and unless and until we do, we will continue to need to raise capital through equity or debt financing. If such equity or debt financing is not available at adequate levels or on acceptable terms, we may need to delay, limit or terminate commercialization and development efforts or discontinue operations. Reverse Stock Split On July 23, 2024, we amended our amended and restated certificate of incorporation to effect a 1-for-10 reverse split of our issued and outstanding shares of common stock. The accompanying financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options and warrants exercisable for common stock and per share amounts contained in our financial statements have been retrospectively adjusted. Also, see Note 10. Condensed Financial Statements Our accompanying unaudited condensed financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and footnote disclosures normally included in the annual financial statements prepared in accordance with the U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations. In our opinion, the unaudited condensed financial statements include all material adjustments, all of which are of a normal and recurring nature, necessary to present fairly our financial position as of June 30, 2024, and our operating results and cash flows for the six month periods ended June 30, 2024 and 2023. The accompanying financial information as of December 31, 2023 is derived from audited financial statements. Interim results are not necessarily indicative of results for a full year. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 21, 2024. Recent Accounting Pronouncements There have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our condensed financial statements. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and classification of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The significant estimates in our financial statements include the valuation of inventory, common stock warrants, and stock-based awards, such as stock options and restricted stock units. Actual results could differ from such estimates. Advertising Costs Advertising costs are expensed as incurred and was $62,000 and $43,000 for the three months ended June 30, 2024 and 2023, respectively, and $121,000 and $84,000 for the six months ended June 30, 2024 and 2023, respectively. Comprehensive Loss We have no other comprehensive income items for the periods presented. As a result, our net loss and comprehensive loss were the same for the periods presented and a separate statement of comprehensive loss is not included in the accompanying condensed financial statements.

BALANCE SHEET COMPONENTS

BALANCE SHEET COMPONENTS	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BALANCE SHEET COMPONENTS	BALANCE SHEET COMPONENTS Cash and Cash Equivalents Highly liquid investments with maturities of three months or less as of the date of acquisition are classified as cash equivalents, of which we had $2.0 million and $5.4 million as of June 30, 2024 and December 31, 2023, respectively, included within cash and cash equivalents in the condensed balance sheets. Accounts Receivable, Net Accounts receivable, net consisted of the following (in thousands): June 30, December 31, Accounts receivable $ 247 $ 99 Allowance for uncollectible accounts (4) (4) Accounts receivable, net $ 243 $ 95 The following was the activity in the allowance for uncollectible accounts (in thousands): Three Months Ended Six Months Ended 2024 2023 2024 2023 Balance as of beginning of period $ 4 $ 4 $ 4 $ 6 Increase in provision 2 — — — Amounts written off, less recoveries (2) — — (2) Balance as of end of period $ 4 $ 4 $ 4 $ 4 Inventory, net Inventory, net consisted of the following (in thousands): June 30, December 31, Raw materials $ 780 $ 747 Work in progress 7 — Finished goods 112 53 Total inventory 899 800 Less: reserve for obsolescence — (5) Inventory, net $ 899 $ 795 The following was the activity in the reserve for obsolescence (in thousands): Three Months Ended Six Months Ended 2024 2023 2024 2023 Balance as of beginning of period $ 5 $ 18 $ 5 $ 18 Increase in reserve — — — — Amounts relieved (5) — (5) — Balance as of end of period $ — $ 18 $ — $ 18 Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets consisted of the following (in thousands): June 30, December 31, Equity offering costs $ 124 $ — Software licenses 116 152 Professional services 48 30 Insurance 47 64 Prepaid inventory 29 111 Other 100 31 Total prepaid expenses and other current assets $ 464 $ 388 Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): June 30, December 31, Research and development equipment $ 1,792 $ 1,763 Office and computer equipment 808 808 Autos 54 54 Furniture and fixtures 46 41 Leasehold improvements 152 141 Total in service 2,852 2,807 Accumulated depreciation and amortization (2,492) (2,419) Property and equipment, net $ 360 $ 388 Accrued Expenses Accrued expenses consisted of the following (in thousands): June 30, December 31, Compensation and related benefits $ 325 $ 232 Legal and consulting professional services 79 121 Product warranty 11 15 Total accrued expenses $ 415 $ 368 Notes Payable In 2023, we arranged financing for the purchase of certain equipment. The notes payable for that certain equipment have a weighted average annual interest rate of 8.9% with a term of five years and is secured by the underlying equipment. As of June 30, 2024, future principal payments were as follows (in thousands): 2024 $ 19 2025 41 2026 45 2027 49 2028 44 Thereafter 3 Total principal payments 201 Less: current portion of notes payable (39) Notes payable, less current portion $ 162

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	6 Months Ended
	Jun. 30, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS The carrying amounts of our financial instruments, including accounts payable and accrued liabilities, approximate fair value due to their short maturities. Notes payable are recorded at amortized cost, which approximates fair value.

LEASES

LEASES	6 Months Ended
	Jun. 30, 2024
Leases [Abstract]
LEASES	LEASES We have operating leases for our corporate headquarters and our manufacturing and research facility, which expire in 2024. The components of lease cost were as follows (in thousands): Three Months Ended Six Months Ended 2024 2023 2024 2023 Operating lease cost $ 57 $ 55 $ 113 $ 111 As of June 30, 2024, maturities of operating lease liabilities were as follows (in thousands): 2024 $ 103 Total operating lease payments 103 Less: imputed interest (2) Total operating lease liabilities $ 101

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION In 2018, our stockholders approved the adoption of the SenesTech, Inc. 2018 Equity Incentive Plan (the “2018 Plan”) which provides for the issuance of stock-based instruments, such as stock options or restricted stock units, to employees or consultants as deemed appropriate. The 2018 Plan has since been amended and restated on certain occasions, most recently on July 11, 2024, when our stockholders approved an increase to the total number of authorized shares to 207,071 shares. Currently, we only have stock options outstanding under the 2018 Plan, which are generally issued with a per share exercise price equal to the fair market value of our common stock at the date of grant. Options granted generally vest immediately, or ratably over a 12- to 36-month period coinciding with their respective service periods, with terms generally of five years. Certain stock option awards provide for accelerated vesting upon a change in control. We have 203,311 shares of common stock available for issuance under the 2018 Plan, which includes the increase to the total number of authorized shares of 200,000 shares approved by our stockholders on July 11, 2024. The following table presents the outstanding stock option activity: Number of Options Weighted Weighted Three months ended June 30, 2024: Outstanding as of March 31, 2024 3,641 $ 1,194.90 3.8 Granted 892 6.740 4.8 Outstanding as of June 30, 2024 4,533 (1) 899.48 3.8 Six months ended June 30, 2024: Outstanding as of December 31, 2023 3,643 1,197.00 4.0 Granted 892 6.740 4.8 Forfeited (2) 1,965.36 3.0 Outstanding as of June 30, 2024 4,533 (1) 899.48 3.8 Exercisable as of June 30, 2024 3,987 1,009.40 3.8 (1) Includes options related to 823 shares that are inducement awards and not granted under the 2018 Plan. The weighted average grant date fair value of options granted during the three months ended June 30, 2024 was $5.59 per share, based on the following assumptions used in the Black-Scholes option pricing model: Expected volatility 117.0 % Expected dividend yield — Expected term (in years) 5 Risk-free interest rate 4.43 % The expected volatility assumption is based on the calculated volatility of our common stock at the date of grant based on historical prices over the most recent period commensurate with the term of the award. The expected dividend yield assumption is based on our history and expected dividend payouts: we have not, and do not expect to, pay dividends. The expected term assumption is the contractual term of the options for non-employees. The risk-free interest rate assumption is determined using the U.S. treasury yields for bonds with a maturity commensurate with the term of the award. The stock-based compensation expense was recorded as follows (in thousands): Three Months Ended Six Months Ended 2024 2023 2024 2023 Research and development $ 4 $ 5 $ 8 $ 9 Selling, general and administrative (1) 84 165 165 327 Total stock-based compensation expense $ 88 $ 170 $ 173 $ 336 (1) Includes $56,000 related to stock issued in exchange for marketing services for the three and six month periods ended June 30, 2023. The allocation between research and development and selling, general and administrative expense was based on the department and services performed by the employee or non-employee. At June 30, 2024, the total compensation cost related to unvested options not yet recognized was $124,000, which will be recognized over a weighted average period of 1.1 years, assuming the employees and non-employees complete their service period required for vesting.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY On July 23, 2024, we amended our amended and restated certificate of incorporation to effect a 1-for-10 reverse split of our issued and outstanding shares of common stock. The accompanying financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options and warrants exercisable for common stock and per share amounts contained in our financial statements have been retrospectively adjusted. Activity in equity during the three and six month periods ended June 30, 2024 and 2023 was as follows (dollars in thousands): Common Stock Additional Accumulated Total Shares Amount 2024 Balances as of December 31, 2023 514,003 $ 1 $ 136,263 $ (129,913) $ 6,351 Stock-based compensation — — 85 — 85 Issuance of common stock upon exercise of warrants 460 — 6 — 6 Net loss — — — (1,832) (1,832) Balances as of March 31, 2024 514,463 1 136,354 (131,745) 4,610 Stock-based compensation — — 88 — 88 Issuance of common stock upon exercise of warrants, net — — — — — Issuance of common stock for fractional shares in the 10:1 reverse stock split 877 — — — — Net loss — — — (1,584) (1,584) Balances as of June 30, 2024 515,340 $ 1 $ 136,442 $ (133,329) $ 3,114 2023 Balances as of December 31, 2022 6,748 $ — $ 127,482 $ (122,203) $ 5,279 Stock-based compensation — — 166 — 166 Issuance of common stock upon exercise of warrants 10,250 — — — — Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes 111 — (11) — (11) Issuance of common stock for service 454 — 100 — 100 Net loss — — — (2,037) (2,037) Balances as of March 31, 2023 17,563 — 127,737 (124,240) 3,497 Stock-based compensation — — 113 — 113 Issuance of common stock, net of issuance costs 7,143 — 1,210 — 1,210 Net loss — — — (1,993) (1,993) Balances as of June 30, 2023 24,706 $ — $ 129,060 $ (126,233) $ 2,827 In June 2024, we entered into an at-the-market offering arrangement with a sales agent, pursuant to which we may offer and sell, from time to time at our sole discretion, in transactions that are deemed to be “at the market” offerings under the Securities Act of 1933, as amended (the “Securities Act”), shares of our common stock for aggregate gross proceeds of up to $1,575,944 (“ATM Facility”). The offer and sale of shares will be made pursuant to a previously filed shelf registration statement on Form S-3 (Registration no. 333-261227), originally filed with the SEC on November 19, 2021 and amended on May 4, 2022, and declared effective by the SEC on May 6, 2022, and the related prospectus supplement related to the offering of shares dated June 20, 2024, and filed with the SEC on such date pursuant to Rule 424(b) under the Securities Act. As of June 30, 2024, we have not sold any shares under this ATM Facility and there are 315,189 shares of common stock reserved for potential issuance under the ATM Facility. The following table presents the common stock warrant activity: Issue Date Warrant Type Term Exercise Balance December 31, 2023 Issued Exercised Expired Balance June 30, 2024 July 2019 Dealer Manager July 2024 $ 81,000.00 3 — — — 3 January 2020 Registered Direct Offering July 2025 $ 21,600.00 60 — — — 60 January 2020 Dealer Manager July 2025 $ 24,000.00 4 — — — 4 March 2020 Dealer Manager March 2025 $ 9,015.12 4 — — — 4 April 2020 Dealer Manager April 2025 $ 9,528.00 47 — — — 47 April 2020 Registered Direct Offering April 2025 $ 7,320.00 20 — — — 20 October 2020 Dealer Manager April 2026 $ 5,174.40 34 — — — 34 February 2021 Private Placement Agreement August 2026 $ 5,318.40 540 — — — 540 February 2021 Dealer Manager August 2026 $ 6,835.40 136 — — — 136 March 2021 Dealer Manager March 2026 $ 6,000.00 60 — — — 60 November 2022 Dealer Manager November 2027 $ 525.000 892 — — — 892 April 2023 Series C October 2028 $ 194.40 7,142 — — — 7,142 April 2023 Dealer Manager April 2028 $ 262.50 534 — — — 534 August 2023 Private Inducement September 2024 $ 86.42 23,809 — — — 23,809 August 2023 Private Inducement August 2028 $ 86.42 25,100 — — — 25,100 August 2023 Dealer Manager August 2028 $ 108.04 1,222 — — — 1,222 November 2023 Series D November 2028 $ 13.00 381,612 — (230) — 381,382 November 2023 Series E May 2025 $ 13.00 307,457 — (230) — 307,227 November 2023 Dealer Manager November 2028 $ 16.25 28,844 — — — 28,844 777,520 — (460) — 777,060 Shares Weighted Weighted Outstanding as of December 31, 2023 777,520 $ 28.79 3.4 Exercised (460) 13.00 — Outstanding as of June 30, 2024 777,060 28.80 2.9 During the six months ended June 30, 2024, warrants representing 460 shares of common stock were exercised with an exercise price of $13.00 per share.

COMMON STOCK WARRANTS

COMMON STOCK WARRANTS	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
COMMON STOCK WARRANTS	STOCKHOLDERS’ EQUITY On July 23, 2024, we amended our amended and restated certificate of incorporation to effect a 1-for-10 reverse split of our issued and outstanding shares of common stock. The accompanying financial statements and notes thereto give retrospective effect to the reverse stock split for all periods presented. All issued and outstanding common stock, options and warrants exercisable for common stock and per share amounts contained in our financial statements have been retrospectively adjusted. Activity in equity during the three and six month periods ended June 30, 2024 and 2023 was as follows (dollars in thousands): Common Stock Additional Accumulated Total Shares Amount 2024 Balances as of December 31, 2023 514,003 $ 1 $ 136,263 $ (129,913) $ 6,351 Stock-based compensation — — 85 — 85 Issuance of common stock upon exercise of warrants 460 — 6 — 6 Net loss — — — (1,832) (1,832) Balances as of March 31, 2024 514,463 1 136,354 (131,745) 4,610 Stock-based compensation — — 88 — 88 Issuance of common stock upon exercise of warrants, net — — — — — Issuance of common stock for fractional shares in the 10:1 reverse stock split 877 — — — — Net loss — — — (1,584) (1,584) Balances as of June 30, 2024 515,340 $ 1 $ 136,442 $ (133,329) $ 3,114 2023 Balances as of December 31, 2022 6,748 $ — $ 127,482 $ (122,203) $ 5,279 Stock-based compensation — — 166 — 166 Issuance of common stock upon exercise of warrants 10,250 — — — — Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes 111 — (11) — (11) Issuance of common stock for service 454 — 100 — 100 Net loss — — — (2,037) (2,037) Balances as of March 31, 2023 17,563 — 127,737 (124,240) 3,497 Stock-based compensation — — 113 — 113 Issuance of common stock, net of issuance costs 7,143 — 1,210 — 1,210 Net loss — — — (1,993) (1,993) Balances as of June 30, 2023 24,706 $ — $ 129,060 $ (126,233) $ 2,827 In June 2024, we entered into an at-the-market offering arrangement with a sales agent, pursuant to which we may offer and sell, from time to time at our sole discretion, in transactions that are deemed to be “at the market” offerings under the Securities Act of 1933, as amended (the “Securities Act”), shares of our common stock for aggregate gross proceeds of up to $1,575,944 (“ATM Facility”). The offer and sale of shares will be made pursuant to a previously filed shelf registration statement on Form S-3 (Registration no. 333-261227), originally filed with the SEC on November 19, 2021 and amended on May 4, 2022, and declared effective by the SEC on May 6, 2022, and the related prospectus supplement related to the offering of shares dated June 20, 2024, and filed with the SEC on such date pursuant to Rule 424(b) under the Securities Act. As of June 30, 2024, we have not sold any shares under this ATM Facility and there are 315,189 shares of common stock reserved for potential issuance under the ATM Facility. The following table presents the common stock warrant activity: Issue Date Warrant Type Term Exercise Balance December 31, 2023 Issued Exercised Expired Balance June 30, 2024 July 2019 Dealer Manager July 2024 $ 81,000.00 3 — — — 3 January 2020 Registered Direct Offering July 2025 $ 21,600.00 60 — — — 60 January 2020 Dealer Manager July 2025 $ 24,000.00 4 — — — 4 March 2020 Dealer Manager March 2025 $ 9,015.12 4 — — — 4 April 2020 Dealer Manager April 2025 $ 9,528.00 47 — — — 47 April 2020 Registered Direct Offering April 2025 $ 7,320.00 20 — — — 20 October 2020 Dealer Manager April 2026 $ 5,174.40 34 — — — 34 February 2021 Private Placement Agreement August 2026 $ 5,318.40 540 — — — 540 February 2021 Dealer Manager August 2026 $ 6,835.40 136 — — — 136 March 2021 Dealer Manager March 2026 $ 6,000.00 60 — — — 60 November 2022 Dealer Manager November 2027 $ 525.000 892 — — — 892 April 2023 Series C October 2028 $ 194.40 7,142 — — — 7,142 April 2023 Dealer Manager April 2028 $ 262.50 534 — — — 534 August 2023 Private Inducement September 2024 $ 86.42 23,809 — — — 23,809 August 2023 Private Inducement August 2028 $ 86.42 25,100 — — — 25,100 August 2023 Dealer Manager August 2028 $ 108.04 1,222 — — — 1,222 November 2023 Series D November 2028 $ 13.00 381,612 — (230) — 381,382 November 2023 Series E May 2025 $ 13.00 307,457 — (230) — 307,227 November 2023 Dealer Manager November 2028 $ 16.25 28,844 — — — 28,844 777,520 — (460) — 777,060 Shares Weighted Weighted Outstanding as of December 31, 2023 777,520 $ 28.79 3.4 Exercised (460) 13.00 — Outstanding as of June 30, 2024 777,060 28.80 2.9 During the six months ended June 30, 2024, warrants representing 460 shares of common stock were exercised with an exercise price of $13.00 per share.

LOSS PER SHARE

LOSS PER SHARE	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
LOSS PER SHARE	LOSS PER SHARE Basic loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding during the period, which includes prefunded warrants and shares held in abeyance from date of issuance. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted average number of common shares used in the basic loss per share calculation plus potentially dilutive securities outstanding during the period determined using the treasury stock method. Stock options and warrants are considered to be potentially dilutive securities but have been excluded from the calculation of diluted loss per share because their effect would be anti-dilutive given the net losses reported for all periods presented. Therefore, basic and diluted loss per share are the same for each period presented. The following shares were excluded from the calculation of diluted net loss per share: Three Months Ended Six Months Ended 2024 2023 2024 2023 Common stock warrants — — — 1,389 Stock options 49 — 167 — Restricted stock units — 85 — 629 49 85 167 2,018

SEGMENT INFORMATION

SEGMENT INFORMATION	6 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION We operate in one segment: the formulation, development, marketing and sale of fertility control products for use in managing pest populations. We generate our revenue from six broad product markets: agribusiness, pest management, facilities management, industrial, consumer, and governmental agencies. Geographic Information Revenue by geographic region was as follows: Three Months Ended Six Months Ended 2024 2023 2024 2023 United States $ 459 $ 305 $ 832 $ 538 International — — 42 — $ 459 $ 305 $ 874 $ 538 Significant Customers The percentage of revenue attributable to our distributors and to customers that represented 10% or more of revenue in at least one of the periods presented, was as follows: Three Months Ended Six Months Ended 2024 2023 2024 2023 All distributors 28 % 2 % 17 % 3 % Distributor A 14 — 7 — The following accounts represented at least 10% of total accounts receivable in at least one of the periods presented: June 30, December 31, Distributor A 32 % 13 % End customer A 3 % 19 % End customer B 2 % 13 %

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	SUBSEQUENT EVENTS On July 11, 2024, we held our annual meeting of stockholders (the “Annual Meeting”), at which meeting our stockholders approved an amendment to our 2018 Plan. The effect of the amendment to the 2018 Plan is to increase the number of shares of common stock available under the 2018 Plan by 200,000 shares. On July 11, 2024, our stockholders also approved a proposal at our Annual Meeting further amending our Amended and Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”), to effect a reverse stock split of our common stock at a ratio between one-for-two (1:2) and one-for-twenty (1:20), without reducing the authorized number of shares of common stock. On July 11, 2024, our board of directors approved a final split ratio of one-for-ten (1:10). Following such approval, we filed an amendment to the Certificate of Incorporation with the Secretary of the State of Delaware on July 23, 2024 to effect the reverse stock split, with an effective date of July 24, 2024. We have evaluated subsequent events from the balance sheet date through August 8, 2024, the date at which the condensed financial statements were issued, and determined that there were no additional items that require adjustment to or disclosure in the condensed financial statements.

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Pay vs Performance Disclosure
Net loss	$ (1,584)	$ (1,832)	$ (1,993)	$ (2,037)	$ (3,416)	$ (4,030)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jun. 30, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Condensed Financial Statements	Condensed Financial Statements
Recent Accounting Pronouncements	Recent Accounting Pronouncements There have been no new accounting pronouncements not yet effective or adopted in the current year that we believe have a significant impact, or potential significant impact, to our condensed financial statements.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts and classification of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. The significant estimates in our financial statements include the valuation of inventory, common stock warrants, and stock-based awards, such as stock options and restricted stock units. Actual results could differ from such estimates.
Comprehensive Loss	Comprehensive Loss We have no other comprehensive income items for the periods presented. As a result, our net loss and comprehensive loss were the same for the periods presented and a separate statement of comprehensive loss is not included in the accompanying condensed financial statements.
Advertising Costs	Advertising Costs Advertising costs are expensed as incurred and was $62,000 and $43,000 for the three months ended June 30, 2024 and 2023, respectively, and $121,000 and $84,000 for the six months ended June 30, 2024 and 2023, respectively.
Cash and Cash Equivalents	Cash and Cash Equivalents Highly liquid investments with maturities of three months or less as of the date of acquisition are classified as cash equivalents, of which we had $2.0 million and $5.4 million as of June 30, 2024 and December 31, 2023, respectively, included within cash and cash equivalents in the condensed balance sheets.

BALANCE SHEET COMPONENTS (Table

BALANCE SHEET COMPONENTS (Tables)	6 Months Ended
	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of accounts receivable, net and activity in allowance for uncollectible accounts	Accounts receivable, net consisted of the following (in thousands): June 30, December 31, Accounts receivable $ 247 $ 99 Allowance for uncollectible accounts (4) (4) Accounts receivable, net $ 243 $ 95 The following was the activity in the allowance for uncollectible accounts (in thousands): Three Months Ended Six Months Ended 2024 2023 2024 2023 Balance as of beginning of period $ 4 $ 4 $ 4 $ 6 Increase in provision 2 — — — Amounts written off, less recoveries (2) — — (2) Balance as of end of period $ 4 $ 4 $ 4 $ 4
Schedule of inventory, net and activity in reserve for obsolescence	Inventory, net consisted of the following (in thousands): June 30, December 31, Raw materials $ 780 $ 747 Work in progress 7 — Finished goods 112 53 Total inventory 899 800 Less: reserve for obsolescence — (5) Inventory, net $ 899 $ 795 The following was the activity in the reserve for obsolescence (in thousands): Three Months Ended Six Months Ended 2024 2023 2024 2023 Balance as of beginning of period $ 5 $ 18 $ 5 $ 18 Increase in reserve — — — — Amounts relieved (5) — (5) — Balance as of end of period $ — $ 18 $ — $ 18
Schedule of prepaid expenses	Prepaid expenses and other current assets consisted of the following (in thousands): June 30, December 31, Equity offering costs $ 124 $ — Software licenses 116 152 Professional services 48 30 Insurance 47 64 Prepaid inventory 29 111 Other 100 31 Total prepaid expenses and other current assets $ 464 $ 388
Schedule of property and equipment, net	Property and equipment, net consisted of the following (in thousands): June 30, December 31, Research and development equipment $ 1,792 $ 1,763 Office and computer equipment 808 808 Autos 54 54 Furniture and fixtures 46 41 Leasehold improvements 152 141 Total in service 2,852 2,807 Accumulated depreciation and amortization (2,492) (2,419) Property and equipment, net $ 360 $ 388
Schedule of accrued expenses	Accrued expenses consisted of the following (in thousands): June 30, December 31, Compensation and related benefits $ 325 $ 232 Legal and consulting professional services 79 121 Product warranty 11 15 Total accrued expenses $ 415 $ 368
Schedule of maturities of notes payable	As of June 30, 2024, future principal payments were as follows (in thousands): 2024 $ 19 2025 41 2026 45 2027 49 2028 44 Thereafter 3 Total principal payments 201 Less: current portion of notes payable (39) Notes payable, less current portion $ 162

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2024
Leases [Abstract]
Schedule of components of lease cost	The components of lease cost were as follows (in thousands): Three Months Ended Six Months Ended 2024 2023 2024 2023 Operating lease cost $ 57 $ 55 $ 113 $ 111
Schedule of future minimum operating lease payments	As of June 30, 2024, maturities of operating lease liabilities were as follows (in thousands): 2024 $ 103 Total operating lease payments 103 Less: imputed interest (2) Total operating lease liabilities $ 101

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of stock option activity	The following table presents the outstanding stock option activity: Number of Options Weighted Weighted Three months ended June 30, 2024: Outstanding as of March 31, 2024 3,641 $ 1,194.90 3.8 Granted 892 6.740 4.8 Outstanding as of June 30, 2024 4,533 (1) 899.48 3.8 Six months ended June 30, 2024: Outstanding as of December 31, 2023 3,643 1,197.00 4.0 Granted 892 6.740 4.8 Forfeited (2) 1,965.36 3.0 Outstanding as of June 30, 2024 4,533 (1) 899.48 3.8 Exercisable as of June 30, 2024 3,987 1,009.40 3.8 (1) Includes options related to 823 shares that are inducement awards and not granted under the 2018 Plan.
Schedule of fair value of options granted, assumptions	The weighted average grant date fair value of options granted during the three months ended June 30, 2024 was $5.59 per share, based on the following assumptions used in the Black-Scholes option pricing model: Expected volatility 117.0 % Expected dividend yield — Expected term (in years) 5 Risk-free interest rate 4.43 %
Schedule of stock-based compensation expense	The stock-based compensation expense was recorded as follows (in thousands): Three Months Ended Six Months Ended 2024 2023 2024 2023 Research and development $ 4 $ 5 $ 8 $ 9 Selling, general and administrative (1) 84 165 165 327 Total stock-based compensation expense $ 88 $ 170 $ 173 $ 336 (1) Includes $56,000 related to stock issued in exchange for marketing services for the three and six month periods ended June 30, 2023.

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Schedule of stockholders' equity activity	Activity in equity during the three and six month periods ended June 30, 2024 and 2023 was as follows (dollars in thousands): Common Stock Additional Accumulated Total Shares Amount 2024 Balances as of December 31, 2023 514,003 $ 1 $ 136,263 $ (129,913) $ 6,351 Stock-based compensation — — 85 — 85 Issuance of common stock upon exercise of warrants 460 — 6 — 6 Net loss — — — (1,832) (1,832) Balances as of March 31, 2024 514,463 1 136,354 (131,745) 4,610 Stock-based compensation — — 88 — 88 Issuance of common stock upon exercise of warrants, net — — — — — Issuance of common stock for fractional shares in the 10:1 reverse stock split 877 — — — — Net loss — — — (1,584) (1,584) Balances as of June 30, 2024 515,340 $ 1 $ 136,442 $ (133,329) $ 3,114 2023 Balances as of December 31, 2022 6,748 $ — $ 127,482 $ (122,203) $ 5,279 Stock-based compensation — — 166 — 166 Issuance of common stock upon exercise of warrants 10,250 — — — — Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes 111 — (11) — (11) Issuance of common stock for service 454 — 100 — 100 Net loss — — — (2,037) (2,037) Balances as of March 31, 2023 17,563 — 127,737 (124,240) 3,497 Stock-based compensation — — 113 — 113 Issuance of common stock, net of issuance costs 7,143 — 1,210 — 1,210 Net loss — — — (1,993) (1,993) Balances as of June 30, 2023 24,706 $ — $ 129,060 $ (126,233) $ 2,827

COMMON STOCK WARRANTS (Tables)

COMMON STOCK WARRANTS (Tables)	6 Months Ended
	Jun. 30, 2024
Equity [Abstract]
Schedule of common stock warrant activity	The following table presents the common stock warrant activity: Issue Date Warrant Type Term Exercise Balance December 31, 2023 Issued Exercised Expired Balance June 30, 2024 July 2019 Dealer Manager July 2024 $ 81,000.00 3 — — — 3 January 2020 Registered Direct Offering July 2025 $ 21,600.00 60 — — — 60 January 2020 Dealer Manager July 2025 $ 24,000.00 4 — — — 4 March 2020 Dealer Manager March 2025 $ 9,015.12 4 — — — 4 April 2020 Dealer Manager April 2025 $ 9,528.00 47 — — — 47 April 2020 Registered Direct Offering April 2025 $ 7,320.00 20 — — — 20 October 2020 Dealer Manager April 2026 $ 5,174.40 34 — — — 34 February 2021 Private Placement Agreement August 2026 $ 5,318.40 540 — — — 540 February 2021 Dealer Manager August 2026 $ 6,835.40 136 — — — 136 March 2021 Dealer Manager March 2026 $ 6,000.00 60 — — — 60 November 2022 Dealer Manager November 2027 $ 525.000 892 — — — 892 April 2023 Series C October 2028 $ 194.40 7,142 — — — 7,142 April 2023 Dealer Manager April 2028 $ 262.50 534 — — — 534 August 2023 Private Inducement September 2024 $ 86.42 23,809 — — — 23,809 August 2023 Private Inducement August 2028 $ 86.42 25,100 — — — 25,100 August 2023 Dealer Manager August 2028 $ 108.04 1,222 — — — 1,222 November 2023 Series D November 2028 $ 13.00 381,612 — (230) — 381,382 November 2023 Series E May 2025 $ 13.00 307,457 — (230) — 307,227 November 2023 Dealer Manager November 2028 $ 16.25 28,844 — — — 28,844 777,520 — (460) — 777,060 Shares Weighted Weighted Outstanding as of December 31, 2023 777,520 $ 28.79 3.4 Exercised (460) 13.00 — Outstanding as of June 30, 2024 777,060 28.80 2.9

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2024
Earnings Per Share [Abstract]
Schedule of outstanding potentially dilutive securities	The following shares were excluded from the calculation of diluted net loss per share: Three Months Ended Six Months Ended 2024 2023 2024 2023 Common stock warrants — — — 1,389 Stock options 49 — 167 — Restricted stock units — 85 — 629 49 85 167 2,018

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2024
Segment Reporting [Abstract]
Schedule of revenue by geographic region	Revenue by geographic region was as follows: Three Months Ended Six Months Ended 2024 2023 2024 2023 United States $ 459 $ 305 $ 832 $ 538 International — — 42 — $ 459 $ 305 $ 874 $ 538
Schedule of customers and distributors that accounted for 10% or more of total revenue and accounts receivable	The percentage of revenue attributable to our distributors and to customers that represented 10% or more of revenue in at least one of the periods presented, was as follows: Three Months Ended Six Months Ended 2024 2023 2024 2023 All distributors 28 % 2 % 17 % 3 % Distributor A 14 — 7 — The following accounts represented at least 10% of total accounts receivable in at least one of the periods presented: June 30, December 31, Distributor A 32 % 13 % End customer A 3 % 19 % End customer B 2 % 13 %

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details) $ in Thousands	3 Months Ended		6 Months Ended		8 Months Ended
	Jun. 30, 2024 USD ($) territory state	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) territory state	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($) territory state	Dec. 31, 2023 USD ($)
Organization and Description of Business [Line Items]
Number of states registration received	50		50		50
Number of states approved removal of RUP designation	49		49		49
Number of major U.S. territories registration received | territory	5		5		5
Accumulated deficit | $	$ 133,329		$ 133,329		$ 133,329	$ 129,913
Cash and cash equivalents | $	1,952		1,952		$ 1,952	$ 5,395
Advertising costs | $	$ 62	$ 43	$ 121	$ 84
Evolve
Organization and Description of Business [Line Items]
Number of states authorized to sell product					43
Evolve Mouse
Organization and Description of Business [Line Items]
Number of states authorized to sell product					32

BALANCE SHEET COMPONENTS - Narr

BALANCE SHEET COMPONENTS - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 5,395	$ 1,952
Debt Instrument [Line Items]
Cash and cash equivalents	$ 5,395	$ 1,952
Notes Payable
Debt Instrument [Line Items]
Debt, annual interest rate	8.90%
Debt, term	5 years

BALANCE SHEET COMPONENTS - Sche

BALANCE SHEET COMPONENTS - Schedule of accounts receivable, net (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts receivable	$ 247		$ 99
Allowance for uncollectible accounts	(4)	$ (4)	(4)	$ (4)	$ (4)	$ (6)
Accounts receivable, net	$ 243		$ 95

BALANCE SHEET COMPONENTS - Sc_2

BALANCE SHEET COMPONENTS - Schedule of allowance for uncollectible accounts (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Accounts Receivable, Allowance for Credit Loss [Roll Forward]
Balance as of beginning of period	$ 4	$ 4	$ 4	$ 6
Increase in provision	2	0	0	0
Amounts written off, less recoveries	(2)	0	0	(2)
Balance as of end of period	$ 4	$ 4	$ 4	$ 4

BALANCE SHEET COMPONENTS - Sc_3

BALANCE SHEET COMPONENTS - Schedule of inventory, net (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 780		$ 747
Work in progress	7		0
Finished goods	112		53
Total inventory	899		800
Less: reserve for obsolescence	0	$ (5)	(5)	$ (18)	$ (18)	$ (18)
Inventory, net	$ 899		$ 795

BALANCE SHEET COMPONENTS - Sc_4

BALANCE SHEET COMPONENTS - Schedule of activity in reserve for obsolescence (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Inventory, Valuation Reserves [Roll Forward]
Balance as of beginning of period	$ 5	$ 18	$ 5	$ 18
Increase in reserve	0	0	0	0
Amounts relieved	(5)	0	(5)	0
Balance as of end of period	$ 0	$ 18	$ 0	$ 18

BALANCE SHEET COMPONENTS - Sc_5

BALANCE SHEET COMPONENTS - Schedule of prepaid expenses (Details) - USD ($)	Jun. 30, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Equity offering costs	$ 124,000	$ 0
Software licenses	116,000	152,000
Professional services	48,000	30,000
Insurance	47,000	64,000
Prepaid inventory	29,000	111,000
Other	100,000	31,000
Total prepaid expenses and other current assets	$ 464,000	$ 388,000

BALANCE SHEET COMPONENTS - Sc_6

BALANCE SHEET COMPONENTS - Schedule of property and equipment, net (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Accumulated depreciation and amortization	$ (2,492)	$ (2,419)
Property and equipment, net	360	388
Depreciable Property, Plant and Equipment
Property, Plant and Equipment [Line Items]
Total in service	2,852	2,807
Research and development equipment
Property, Plant and Equipment [Line Items]
Total in service	1,792	1,763
Office and computer equipment
Property, Plant and Equipment [Line Items]
Total in service	808	808
Autos
Property, Plant and Equipment [Line Items]
Total in service	54	54
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total in service	46	41
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total in service	$ 152	$ 141

BALANCE SHEET COMPONENTS - Sc_7

BALANCE SHEET COMPONENTS - Schedule of accrued expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Dec. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Compensation and related benefits	$ 325	$ 232
Legal and consulting professional services	79	121
Product warranty	11	15
Total accrued expenses	$ 415	$ 368

BALANCE SHEET COMPONENTS - Sc_8

BALANCE SHEET COMPONENTS - Schedule of notes payable maturities (Details) - Notes Payable $ in Thousands	Jun. 30, 2024 USD ($)
Debt Instrument [Line Items]
2024	$ 19
2025	41
2026	45
2027	49
2028	44
Thereafter	3
Total principal payments	201
Less: current portion of notes payable	(39)
Notes payable, less current portion	$ 162

LEASES - Schedule of lease cost

LEASES - Schedule of lease cost (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Leases [Abstract]
Operating lease cost	$ 57	$ 55	$ 113	$ 111

LEASES - Schedule of maturities

LEASES - Schedule of maturities of operating leases liabilities (Details) $ in Thousands	Jun. 30, 2024 USD ($)
Leases [Abstract]
2023	$ 103
Total operating lease payments	103
Less: imputed interest	(2)
Total operating lease liabilities	$ 101

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	6 Months Ended	9 Months Ended
	Jul. 11, 2024	Jun. 30, 2024	Jun. 30, 2024	Sep. 30, 2019
Stock-Based Compensation (Details) [Line Items]
Common stock, available for issuance (in shares)		315,189	315,189
2018 Equity Incentive Plan
Stock-Based Compensation (Details) [Line Items]
Shares authorized (in shares)		207,071	207,071
Common stock, available for issuance (in shares)		203,311	203,311
Number of additional shares authorized (in shares)			200,000
Unrecognized compensation cost		$ 124	$ 124
2018 Equity Incentive Plan | Subsequent Event
Stock-Based Compensation (Details) [Line Items]
Number of additional shares authorized (in shares)	200,000
2018 Equity Incentive Plan | Stock Options
Stock-Based Compensation (Details) [Line Items]
Options, term				5 years
Weighted average grant date fair value (in dollars per share)		$ 5.59
Unrecognized compensation cost, period of recognition			1 year 1 month 6 days
2018 Equity Incentive Plan | Minimum | Stock Options
Stock-Based Compensation (Details) [Line Items]
Options, vesting period				12 months
2018 Equity Incentive Plan | Maximum | Stock Options
Stock-Based Compensation (Details) [Line Items]
Options, vesting period				36 months

STOCK-BASED COMPENSATION - Sche

STOCK-BASED COMPENSATION - Schedule of stock option activity (Details) - $ / shares	3 Months Ended		6 Months Ended	12 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2024	Dec. 31, 2023
Number of Options
Beginning Balance (in shares)	3,641	3,643	3,643
Granted (in shares)	892		892
Forfeited (in shares)			(2)
Ending Balance (in shares)	4,533	3,641	4,533	3,643
Exercisable (in shares)	3,987		3,987
Weighted Average Exercise Price Per Share
Beginning Balance (in dollars per share)	$ 1,194.9	$ 1,197	$ 1,197
Granted (in dollars per share)	6.740		6.740
Forfeited (in dollars per share)			1,965.36
Ending Balance (in dollars per share)	899.48	$ 1,194.9	899.48	$ 1,197
Exercisable (in dollars per share)	$ 1,009.4		$ 1,009.4
Weighted Average Remaining Contractual Term (years)
Outstanding	3 years 9 months 18 days	3 years 9 months 18 days	3 years 9 months 18 days	4 years
Granted	4 years 9 months 18 days		4 years 9 months 18 days
Forfeited			$ 3
Exercisable			3 years 9 months 18 days
Stock Options, Inducement Awards
Number of Options
Ending Balance (in shares)	823		823

STOCK-BASED COMPENSATION - Sc_2

STOCK-BASED COMPENSATION - Schedule of fair value option assumptions (Details) - 2018 Equity Incentive Plan - Stock Options	3 Months Ended
	Jun. 30, 2024
Stock-Based Compensation (Details) [Line Items]
Expected volatility	117%
Expected dividend yield	0%
Expected term (in years)	5 years
Risk-free interest rate	4.43%

STOCK-BASED COMPENSATION - Sc_3

STOCK-BASED COMPENSATION - Schedule of stock-based compensation expense (Details) - USD ($) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Stock-Based Compensation (Details) [Line Items]
Total stock-based compensation expense	$ 88	$ 170		$ 173	$ 336
Issuance of common stock for service			$ 100
Research and development
Stock-Based Compensation (Details) [Line Items]
Total stock-based compensation expense	4	5		8	9
Selling, general and administrative
Stock-Based Compensation (Details) [Line Items]
Total stock-based compensation expense	$ 84	165		$ 165	327
Issuance of common stock for service		$ 56			$ 56

STOCK-BASED COMPENSATION - Sc_4

STOCK-BASED COMPENSATION - Schedule of fair value of options granted assumptions (Details) - Stock Options - 2018 Equity Incentive Plan	3 Months Ended
	Jun. 30, 2024
Stock-Based Compensation (Details) [Line Items]
Expected volatility	117%
Expected dividend yield	0%
Expected term (in years)	5 years
Risk-free interest rate	4.43%

STOCKHOLDERS' EQUITY - Narrativ

STOCKHOLDERS' EQUITY - Narrative (Details)	Jul. 23, 2024	Jun. 30, 2024 USD ($) shares
Stockholders’ Equity [Line Items]
Shelf registration, future offering availability, amount | $		$ 1,575,944
Common stock, available for issuance (in shares) | shares		315,189
Subsequent Event
Stockholders’ Equity [Line Items]
Reverse stock split ratio, common stock	0.10

STOCKHOLDERS' EQUITY - Activity

STOCKHOLDERS' EQUITY - Activity in stockholders' equity (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2023	Mar. 31, 2023	Jun. 30, 2024	Jun. 30, 2023
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance (in shares)		514,003			514,003
Beginning Balance	$ 4,610	$ 6,351	$ 3,497	$ 5,279	$ 6,351	$ 5,279
Stock-based compensation	88	85	113	166
Issuance of common stock upon exercise of warrants, net		6
Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes				(11)
Issuance of common stock for service				100
Issuance of common stock, net of issuance costs			1,210
Net loss	$ (1,584)	(1,832)	(1,993)	(2,037)	$ (3,416)	(4,030)
Ending Balance (in shares)	515,340				515,340
Ending Balance	$ 3,114	$ 4,610	$ 2,827	$ 3,497	$ 3,114	$ 2,827
Common Stock
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance (in shares)	514,463	514,003	17,563	6,748	514,003	6,748
Beginning Balance	$ 1	$ 1	$ 0	$ 0	$ 1	$ 0
Issuance of common stock upon exercise of warrants (in shares)		460		10,250
Issuance of common stock for fractional shares in the 10:1 reverse stock split (in shares)	877
Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes (in shares)				111
Issuance of common stock for service (in shares)				454
Issuance of common stock, net of issuance costs (in shares)			7,143
Ending Balance (in shares)	515,340	514,463	24,706	17,563	515,340	24,706
Ending Balance	$ 1	$ 1	$ 0	$ 0	$ 1	$ 0
Additional Paid-In Capital
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	136,354	136,263	127,737	127,482	136,263	127,482
Stock-based compensation	88	85	113	166
Issuance of common stock upon exercise of warrants, net		6
Issuance of shares pursuant to the vesting of restricted stock units, net of shares withheld for taxes				(11)
Issuance of common stock for service				100
Issuance of common stock, net of issuance costs			1,210
Ending Balance	136,442	136,354	129,060	127,737	136,442	129,060
Accumulated Deficit
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Beginning Balance	(131,745)	(129,913)	(124,240)	(122,203)	(129,913)	(122,203)
Net loss	(1,584)	(1,832)	(1,993)	(2,037)
Ending Balance	$ (133,329)	$ (131,745)	$ (126,233)	$ (124,240)	$ (133,329)	$ (126,233)

COMMON STOCK WARRANTS - Schedul

COMMON STOCK WARRANTS - Schedule of common stock warrant activity (Details) - $ / shares	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Class of Warrant or Right [Line Items]
Exercise Price (in dollars per share)	$ 28.80	$ 28.79
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	777,520
Issued (in shares)	0
Exercised (in shares)	(460)
Expired (in shares)	0
Ending Balance (in shares)	777,060
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type	Dealer Manager
Term Date	July 2024
Exercise Price (in dollars per share)	$ 81,000
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	3
Issued (in shares)	0
Exercised (in shares)	0
Expired (in shares)	0
Ending Balance (in shares)	3
Registered Direct Offering
Class of Warrant or Right [Line Items]
Warrant Type	Registered Direct Offering
Term Date	July 2025
Exercise Price (in dollars per share)	$ 21,600
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	60
Issued (in shares)	0
Exercised (in shares)	0
Expired (in shares)	0
Ending Balance (in shares)	60
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type	Dealer Manager
Term Date	July 2025
Exercise Price (in dollars per share)	$ 24,000
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	4
Issued (in shares)	0
Exercised (in shares)	0
Expired (in shares)	0
Ending Balance (in shares)	4
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type	Dealer Manager
Term Date	March 2025
Exercise Price (in dollars per share)	$ 9,015.12
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	4
Issued (in shares)	0
Exercised (in shares)	0
Expired (in shares)	0
Ending Balance (in shares)	4
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type	Dealer Manager
Term Date	April 2025
Exercise Price (in dollars per share)	$ 9,528
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	47
Issued (in shares)	0
Exercised (in shares)	0
Expired (in shares)	0
Ending Balance (in shares)	47
Registered Direct Offering
Class of Warrant or Right [Line Items]
Warrant Type	Registered Direct Offering
Term Date	April 2025
Exercise Price (in dollars per share)	$ 7,320
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	20
Issued (in shares)	0
Exercised (in shares)	0
Expired (in shares)	0
Ending Balance (in shares)	20
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type	Dealer Manager
Term Date	April 2026
Exercise Price (in dollars per share)	$ 5,174.4
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	34
Issued (in shares)	0
Exercised (in shares)	0
Expired (in shares)	0
Ending Balance (in shares)	34
Private Placement Agreement
Class of Warrant or Right [Line Items]
Warrant Type	Private Placement Agreement
Term Date	August 2026
Exercise Price (in dollars per share)	$ 5,318.4
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	540
Issued (in shares)	0
Exercised (in shares)	0
Expired (in shares)	0
Ending Balance (in shares)	540
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type	Dealer Manager
Term Date	August 2026
Exercise Price (in dollars per share)	$ 6,835.4
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	136
Issued (in shares)	0
Exercised (in shares)	0
Expired (in shares)	0
Ending Balance (in shares)	136
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type	Dealer Manager
Term Date	March 2026
Exercise Price (in dollars per share)	$ 6,000
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	60
Issued (in shares)	0
Exercised (in shares)	0
Expired (in shares)	0
Ending Balance (in shares)	60
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type	Dealer Manager
Term Date	November 2027
Exercise Price (in dollars per share)	$ 525
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	892
Issued (in shares)	0
Exercised (in shares)	0
Expired (in shares)	0
Ending Balance (in shares)	892
Series C
Class of Warrant or Right [Line Items]
Warrant Type	Series C
Term Date	October 2028
Exercise Price (in dollars per share)	$ 194.40
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	7,142
Issued (in shares)	0
Exercised (in shares)	0
Expired (in shares)	0
Ending Balance (in shares)	7,142
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type	Dealer Manager
Term Date	April 2028
Exercise Price (in dollars per share)	$ 262.50
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	534
Issued (in shares)	0
Exercised (in shares)	0
Expired (in shares)	0
Ending Balance (in shares)	534
Private Inducement
Class of Warrant or Right [Line Items]
Warrant Type	Private Inducement
Term Date	September 2024
Exercise Price (in dollars per share)	$ 86.42
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	23,809
Issued (in shares)	0
Exercised (in shares)	0
Expired (in shares)	0
Ending Balance (in shares)	23,809
Private Inducement
Class of Warrant or Right [Line Items]
Warrant Type	Private Inducement
Term Date	August 2028
Exercise Price (in dollars per share)	$ 86.42
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	25,100
Issued (in shares)	0
Exercised (in shares)	0
Expired (in shares)	0
Ending Balance (in shares)	25,100
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type	Dealer Manager
Term Date	August 2028
Exercise Price (in dollars per share)	$ 108.04
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	1,222
Issued (in shares)	0
Exercised (in shares)	0
Expired (in shares)	0
Ending Balance (in shares)	1,222
Series D
Class of Warrant or Right [Line Items]
Warrant Type	Series D
Term Date	November 2028
Exercise Price (in dollars per share)	$ 13
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	381,612
Issued (in shares)	0
Exercised (in shares)	(230)
Expired (in shares)	0
Ending Balance (in shares)	381,382
Series E
Class of Warrant or Right [Line Items]
Warrant Type	Series E
Term Date	May 2025
Exercise Price (in dollars per share)	$ 13
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	307,457
Issued (in shares)	0
Exercised (in shares)	(230)
Expired (in shares)	0
Ending Balance (in shares)	307,227
Dealer Manager
Class of Warrant or Right [Line Items]
Warrant Type	Dealer Manager
Term Date	November 2028
Exercise Price (in dollars per share)	$ 16.25
Class of Warrant or Right, Outstanding [Roll Forward]
Beginning Balance (in shares)	28,844
Issued (in shares)	0
Exercised (in shares)	0
Expired (in shares)	0
Ending Balance (in shares)	28,844

COMMON STOCK WARRANTS - Sched_2

COMMON STOCK WARRANTS - Schedule of common stock warrant activity for the period (Details) - $ / shares	3 Months Ended	6 Months Ended
	Mar. 31, 2024	Jun. 30, 2024
Shares
Beginning Balance (in shares)	777,520	777,520
Exercised (in shares)		(460)
Ending Balance (in shares)		777,060
Weighted Average Exercise Price Per Share
Beginning Balance (in dollars per share)	$ 28.79	$ 28.79
Exercised (in dollars per share)		13
Ending Balance (in dollars per share)		$ 28.80
Weighted Average Remaining Contractual Term (years)
Outstanding (in years)	3 years 4 months 24 days	2 years 10 months 24 days

COMMON STOCK WARRANTS - Narrati

COMMON STOCK WARRANTS - Narrative (Details)	6 Months Ended
	Jun. 30, 2024 $ / shares shares
Class of Warrant or Right [Line Items]
Warrants, exercised (in shares) | shares	460
Warrants, exercised (in dollars per share) | $ / shares	$ 13
PreFunded Warrants, Issued in November 2022, Common Stock, Registered Direct Offering
Class of Warrant or Right [Line Items]
Warrants, exercised (in shares) | shares	460
Warrants, exercised (in dollars per share) | $ / shares	$ 13

LOSS PER SHARE -Schedule of out

LOSS PER SHARE -Schedule of outstanding potentially dilutive securities (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	49	85	167	2,018
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	0	0	0	1,389
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	49	0	167	0
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total (in shares)	0	85	0	629

SEGMENT INFORMATION - Narrative

SEGMENT INFORMATION - Narrative (Details)	6 Months Ended
	Jun. 30, 2024 segement
Segment Reporting [Abstract]
Number of operating segments	1

SEGMENT INFORMATION - Revenue b

SEGMENT INFORMATION - Revenue by Geographic Region (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues, net	$ 459	$ 305	$ 874	$ 538
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues, net	459	305	832	538
International
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues, net	$ 0	$ 0	$ 42	$ 0

SEGMENT INFORMATION - Revenue C

SEGMENT INFORMATION - Revenue Concentration Risk Percentage (Details) - Revenue Benchmark - Customer Concentration Risk	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023
All distributors
Revenue, Major Customer [Line Items]
Percentage of accounts receivable	28%	2%	17%	3%
Distributor A
Revenue, Major Customer [Line Items]
Percentage of accounts receivable	14%	0%	7%	0%

SEGMENT INFORMATION - Accounts

SEGMENT INFORMATION - Accounts Receivable Concentration Risk Percentage (Details) - Accounts Receivable Benchmark - Customer Concentration Risk	6 Months Ended	12 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Distributor A
Revenue, Major Customer [Line Items]
Percentage of accounts receivable	32%	13%
End customer A
Revenue, Major Customer [Line Items]
Percentage of accounts receivable	3%	19%
End customer B
Revenue, Major Customer [Line Items]
Percentage of accounts receivable	2%	13%

SUBSEQUENT EVENTS - Narrative (

SUBSEQUENT EVENTS - Narrative (Details) - 2018 Equity Incentive Plan - shares		6 Months Ended
	Jul. 11, 2024	Jun. 30, 2024
Subsequent Event [Line Items]
Number of additional shares authorized (in shares)		200,000
Shares authorized (in shares)		207,071
Subsequent Event
Subsequent Event [Line Items]
Number of additional shares authorized (in shares)	200,000